Nautilus Advisors’s Gilead Sciences GILD Stock Holding History

Nautilus Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.05M	Buy	7,023 +2	+0%	+$281	0.63%	42
2026 Q2	$912K	Buy	7,021 +37	+0.5%	+$4.88K	0.54%	53
2026 Q1	$973K	Sell	6,984 -10	-0.1%	-$1.4K	0.67%	42
2025 Q4	$858K	Sell	6,994 -164	-2%	-$19.9K	0.56%	50
2025 Q3	$795K	Buy	7,158 +1	+0%	+$114	0.53%	52
2025 Q2	$793K	Hold	7,157	–	–	0.58%	44
2025 Q1	$802K	Sell	7,157 -75	-1%	-$7.74K	0.66%	44
2024 Q4	$668K	Buy	+7,232	New	+$651K	0.53%	56

Other funds holding GILD

CIM

Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return

MSV

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

CapWealth Advisors Franklin, Tennessee $1.32B AUM 21.6% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return

SCA

Stokes Capital Advisors Greenwood, South Carolina $455M AUM 9.69% 1-Year Est. Return

Nautilus Advisors's GILD Position: Q3 2026 in Review

Nautilus Advisors increased its Gilead Sciences (GILD) stake by 0.03% in Q3 2026, buying an estimated $281 and bringing the position to 7,023 shares worth $1.05M. The position accounts for 0.63% of the portfolio, ranked #42.

Nautilus Advisors first reported a position in GILD in Q4 2024 and has held it in 8 quarters since. 119 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

Nautilus Advisors held 7,023 shares of Gilead Sciences worth $1.05M as of Q3 2026.
Nautilus Advisors bought 2 Gilead Sciences shares in Q3 2026, an estimated $281.
Gilead Sciences made up 0.63% of Nautilus Advisors's portfolio in Q3 2026, its #42 holding.
Nautilus Advisors first reported a position in Gilead Sciences in Q4 2024 and has held it in 8 quarters since.
119 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Nautilus Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.